# Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Source: https://onco.cc/trials/nct07473167/  
OnCo record `nct07473167` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TC011 in diffuse large b-cell lymphoma and follicular lymphoma, run by TICAROS Co., Ltd., now recruiting.

## Summary

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients is a phase 1/2 interventional study registered as NCT07473167 by TICAROS Co., Ltd., with 98 participants planned, started 2023-08-03 and due to reach its primary completion in 2028-02-11. Interventions recorded: TC011. Conditions listed: Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High-grade B-cell Lymphoma (HGBL). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07473167
- Phase: 1/2
- Setting: A Multi-center, Single Arm, Open-label Phase 1/2 Clinical Trial to Evaluate Safety, and to Explore Efficacy of TC011(CD19 Targeted CAR-T) in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
- Sponsor: TICAROS Co., Ltd.
- Enrolled: 98

## Sources

- ClinicalTrials.gov NCT07473167: https://clinicaltrials.gov/study/NCT07473167

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [TC011](https://onco.cc/drugs/tc011/)

---
JSON: https://onco.cc/api/v1/entities/nct07473167.json